Nesina
Total Payments
$607,605
Transactions
468
Doctors
202
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $402,628 | 80 | 2 |
| 2018 | $137,357 | 88 | 1 |
| 2017 | $67,620 | 300 | 199 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $551,449 | 205 | 90.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,273 | 5 | 5.3% |
| Travel and Lodging | $10,655 | 5 | 1.8% |
| Consulting Fee | $10,175 | 1 | 1.7% |
| Food and Beverage | $3,053 | 252 | 0.5% |
Payments by Type
Research
$551,449
205 transactions
General
$56,156
263 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus | Takeda Pharmaceuticals U.S.A., Inc. | $536,993 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus | Takeda Development Center Americas, Inc. | $8,000 | 0 |
| Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes | Takeda Development Center Americas, Inc. | $6,033 | 1 |
| Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes | Takeda Pharmaceuticals U.S.A., Inc. | $422.70 | 0 |
Top Doctors Receiving Payments for Nesina
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Secaucus, NJ | $542,591 | 200 |
| , DO | Cardiovascular Disease | San Antonio, TX | $39,729 | 6 |
| , MD | Cardiovascular Disease | Baltimore, MD | $10,745 | 4 |
| , MBBS, MS | Pediatric Gastroenterology | Los Angeles, CA | $7,800 | 2 |
| , MD, PH.D | Endocrinology, Diabetes & Metabolism | Boston, MA | $2,557 | 2 |
| , MD | Hypertension Specialist | Farmington, CT | $1,057 | 3 |
| , MD | Cardiovascular Disease | Kansas City, MO | $323.75 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Westminster, CA | $118.54 | 8 |
| , MD | Endocrinology, Diabetes & Metabolism | Fountain Valley, CA | $109.76 | 8 |
| , MD | Endocrinology, Diabetes & Metabolism | New York, NY | $48.44 | 2 |
| , MD | Family Medicine | Northridge, CA | $45.81 | 2 |
| , M.D | Internal Medicine | Elgin, IL | $37.13 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | Huntington Beach, CA | $32.45 | 3 |
| , M.D | Gynecology | Lanham, MD | $30.21 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Great Neck, NY | $29.54 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Tucson, AZ | $28.86 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $28.10 | 2 |
| , MD | Internal Medicine | Mesa, AZ | $26.81 | 1 |
| , DO | Internal Medicine | Fall River, MA | $24.49 | 2 |
| , MD | Internal Medicine | Las Vegas, NV | $24.00 | 1 |
| , M.D | Internal Medicine | New Milford, CT | $23.83 | 4 |
| , MD | Endocrinology, Diabetes & Metabolism | Memphis, TN | $23.31 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Memphis, TN | $23.31 | 2 |
| , M.D | Family Medicine | Brea, CA | $22.97 | 2 |
| , DO | Family Medicine | Mesa, AZ | $22.97 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $607,605
- Total Doctors 202
- Transactions 468
About Nesina
Nesina is a drug associated with $607,605 in payments to 202 healthcare providers, recorded across 468 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2019. In 2019, $402,628 was paid across 80 transactions to 2 doctors.
The most common payment nature for Nesina is "Unspecified" ($551,449, 90.8% of total).
Nesina is associated with 4 research studies, including "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus" ($536,993).